Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorundrostat in Obstructive Sleep Apnea and Hypertension
NCT06785454Phase 2Completed
- Sponsor
- Mineralys Therapeutics
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lorundrostat in obstructive sleep apnea (OSA), hypertension (HTN), sponsored by Mineralys Therapeutics. Started Feb 2025; status: completed.
02
Drugs
lorundrostat
03
Conditions
obstructive sleep apnea (OSA)hypertension (HTN)
Beyond the preview
Go deeper on NCT06785454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06785454.